{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:53:30Z","timestamp":1791431610269,"version":"4.3.3"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA037820"],"award-info":[{"award-number":["R01DA037820"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA054190"],"award-info":[{"award-number":["R01DA054190"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA020024"],"award-info":[{"award-number":["UG1DA020024"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01DA036267"],"award-info":[{"award-number":["U01DA036267"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30MH058107"],"award-info":[{"award-number":["P30MH058107"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.mcna.2021.08.010","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T16:58:30Z","timestamp":1637600310000},"page":"81-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Understanding Stimulant Use and Use Disorders in a New Era"],"prefix":"10.1016","volume":"106","author":[{"given":"Daniel","family":"Ciccarone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Shoptaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6408","key":"10.1016\/j.mcna.2021.08.010_bib1","doi-asserted-by":"crossref","first-page":"eaau1184","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.mcna.2021.08.010_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.mcna.2021.08.010_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: a rapidly changing risk environment","volume":"46","author":"Ciccarone","year":"2017","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.mcna.2021.08.010_bib4","series-title":"2019 Annual Surveillance Report of Drug-Related Risks and Outcomes \u2014 United States Surveillance","year":"2019"},{"key":"10.1016\/j.mcna.2021.08.010_bib5","series-title":"Key Substance use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health","year":"2020"},{"key":"10.1016\/j.mcna.2021.08.010_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugalcdep.2017.10.011","article-title":"Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington","volume":"182","author":"Glick","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib7","series-title":"Law Enforcement Seizures of MethamPhetamine Widespread and Increasing","author":"Artigiani","year":"2020"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib8","first-page":"85","article-title":"Rise in presence of methamphetamine in oral fluid toxicology tests among outpatients in a large healthcare setting in the Northeast","volume":"15","author":"Wakeman","year":"2021","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mcna.2021.08.010_bib9","series-title":"2020 National Drug Threat Assessment","year":"2021"},{"issue":"4","key":"10.1016\/j.mcna.2021.08.010_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.mcna.2021.08.010_bib11","series-title":"Drug overdose deaths in the United States, 1999\u20132018. NCHS Data Brief, no 356.","author":"Hedegaard","year":"2020"},{"issue":"5","key":"10.1016\/j.mcna.2021.08.010_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jamapsychiatry.2020.4321","article-title":"Methamphetamine overdose deaths in the US by sex and race and ethnicity","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"34","key":"10.1016\/j.mcna.2021.08.010_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","article-title":"Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine - 25 states, July- December 2017 to January-June 2018","volume":"68","author":"Gladden","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"10.1016\/j.mcna.2021.08.010_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the united states, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"J\u00a0Am Med Assoc"},{"issue":"8","key":"10.1016\/j.mcna.2021.08.010_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/10826084.2016.1271432","article-title":"Heroin and methamphetamine injection: an emerging drug use pattern","volume":"52","author":"Al-Tayyib","year":"2017","journal-title":"Substance use & misuse"},{"key":"10.1016\/j.mcna.2021.08.010_bib16","series-title":"Co-involvement of opioids in drug overdose deaths involving cocaine and psychostimulants. NCHS Data Brief, no 406.","author":"Hedegaard","year":"2021"},{"key":"10.1016\/j.mcna.2021.08.010_bib17","doi-asserted-by":"crossref","first-page":"107592","DOI":"10.1016\/j.drugalcdep.2019.107592","article-title":"A\u00a0nationally representative analysis of \u201ctwin epidemics\u201d: rising rates of methamphetamine use among persons who use opioids","volume":"204","author":"Strickland","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib19","doi-asserted-by":"crossref","first-page":"116891","DOI":"10.1016\/j.watres.2021.116891","article-title":"International snapshot of new psychoactive substance use: case study of eight countries over the 2019\/2020 new year period","volume":"193","author":"Bade","year":"2021","journal-title":"Water Res"},{"issue":"10209","key":"10.1016\/j.mcna.2021.08.010_bib20","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(19)32231-7","article-title":"New psychoactive substances: challenges for drug surveillance, control, and public health responses","volume":"394","author":"Peacock","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.mcna.2021.08.010_bib21","series-title":"World Drug Report 2020: Booklet 3, drug Supply","year":"2020"},{"key":"10.1016\/j.mcna.2021.08.010_bib22","series-title":"2019 National drug threat assessment","year":"2020"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pop.2010.11.004","article-title":"Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy","volume":"38","author":"Ciccarone","year":"2011","journal-title":"Prim Care"},{"issue":"7","key":"10.1016\/j.mcna.2021.08.010_bib26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1360-0443.2009.02564.x","article-title":"A\u00a0review of the clinical pharmacology of methamphetamine","volume":"104","author":"Cruickshank","year":"2009","journal-title":"Addiction (Abingdon, England)"},{"issue":"4","key":"10.1016\/j.mcna.2021.08.010_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ccc.2012.07.003","article-title":"Cocaine intoxication","volume":"28","author":"Zimmerman","year":"2012","journal-title":"Crit Care Clin"},{"issue":"12","key":"10.1016\/j.mcna.2021.08.010_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0024-3205(00)00731-1","article-title":"Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain","volume":"67","author":"Volkow","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.mcna.2021.08.010_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: the surging rise of methamphetamine use in chronic opioid users","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.mcna.2021.08.010_bib30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10408444.2019.1679087","article-title":"Synthetic cathinones: an evolving class of new psychoactive substances","volume":"49","author":"Goncalves","year":"2019","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.mcna.2021.08.010_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.pharmtox.47.120505.105140","article-title":"New insights into the mechanism of action of amphetamines","volume":"47","author":"Fleckenstein","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugalcdep.2012.11.016","article-title":"Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings","volume":"129","author":"Panenka","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.mcna.2021.08.010_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","article-title":"Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review","volume":"77","author":"Paulus","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.mcna.2021.08.010_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature","volume":"143","author":"Courtney","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.2009.05144.x","article-title":"Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction","volume":"1187","author":"Schmidt","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mcna.2021.08.010_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neuropharm.2013.07.021","article-title":"Neurobiological mechanisms that contribute to stress-related cocaine use","volume":"76 Pt B","author":"Mantsch","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/add.14713","article-title":"Psychostimulant use disorder and the heart","volume":"115","author":"Duflou","year":"2020","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.mcna.2021.08.010_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0002-9343(90)90484-U","article-title":"Cocaine-related medical problems: consecutive series of 233 patients","volume":"88","author":"Brody","year":"1990","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.mcna.2021.08.010_bib39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1553-2712.2000.tb02064.x","article-title":"Cocaine-associated chest pain: how common is myocardial infarction?","volume":"7","author":"Weber","year":"2000","journal-title":"Acad Emerg Med"},{"issue":"4","key":"10.1016\/j.mcna.2021.08.010_bib40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.hlc.2015.10.019","article-title":"The cardiac complications of methamphetamines","volume":"25","author":"Paratz","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"4","key":"10.1016\/j.mcna.2021.08.010_bib41","first-page":"E89","article-title":"Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm","volume":"19","author":"Chen","year":"2007","journal-title":"J\u00a0Invasive Cardiol"},{"issue":"4","key":"10.1016\/j.mcna.2021.08.010_bib42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.amjcard.2016.05.057","article-title":"Frequency of Methamphetamine Use as a Major Contributor Toward the Severity of Cardiomyopathy in Adults \u226450Years","volume":"118","author":"Neeki","year":"2016","journal-title":"The Am J Cardiol"},{"issue":"5","key":"10.1016\/j.mcna.2021.08.010_bib43","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0002-8703(88)90078-6","article-title":"Cardiovascular effects of cocaine: an autopsy study of 40 patients","volume":"115","author":"Virmani","year":"1988","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.mcna.2021.08.010_bib44","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/1556-4029.14056","article-title":"Psychostimulant use and fatal stroke in young adults","volume":"64","author":"Darke","year":"2019","journal-title":"J\u00a0forensic Sci"},{"issue":"11","key":"10.1016\/j.mcna.2021.08.010_bib45","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/add.14708","article-title":"Psychostimulant use and the brain","volume":"114","author":"Lappin","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11065-007-9031-0","article-title":"Neurocognitive effects of methamphetamine: a critical review and meta-analysis","volume":"17","author":"Scott","year":"2007","journal-title":"Neuropsychol Rev"},{"issue":"2","key":"10.1016\/j.mcna.2021.08.010_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11011-014-9496-5","article-title":"Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors","volume":"29","author":"Akindipe","year":"2014","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.mcna.2021.08.010_bib48","series-title":"HIV Surveillance Report, 2018 (Preliminary)","year":"2019"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1515195","article-title":"HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015","volume":"375","author":"Peters","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.08.010_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6708a6","article-title":"Notes from the field: HIV infection investigation in a rural area \u2014 West Virginia, 2017","volume":"67","author":"Evans","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mcna.2021.08.010_bib52","series-title":"HIV Cluster Identified in Ohio county","year":"2018"},{"key":"10.1016\/j.mcna.2021.08.010_bib53","series-title":"Epi-2: Preliminary Epi-Aid Report: Undetermined Risk Factors and Mode of Transmission for HIV Infection Among Persons Who Inject Drugs \u2014 Massachusetts","year":"2018"},{"issue":"6","key":"10.1016\/j.mcna.2021.08.010_bib54","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00002030-200304110-00014","article-title":"Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic","volume":"17","author":"Tyndall","year":"2003","journal-title":"Aids"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2021.08.010_bib55","first-page":"i120","article-title":"Methamphetamine-using HIV-positive men who have sex with men: correlates of polydrug use","volume":"82","author":"Patterson","year":"2005","journal-title":"J\u00a0Urban Health : Bull New York Acad Med"},{"issue":"8","key":"10.1016\/j.mcna.2021.08.010_bib56","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/01.olq.0000258339.17325.93","article-title":"Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM, San Francisco","volume":"34","author":"Spindler","year":"2007","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/QAI.0000000000001643","article-title":"Brief report: recent methamphetamine use is associated with increased rectal mucosal inflammatory cytokines, regardless of HIV-1 serostatus","volume":"78","author":"Fulcher","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.mcna.2021.08.010_bib58","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.addbeh.2011.02.001","article-title":"Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users","volume":"36","author":"Fairbairn","year":"2011","journal-title":"Addict Behav"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2021.08.010_bib59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2010.11.004","article-title":"Probability and Predictors of Transition from First Use to Dependence on Nicotine, Alcohol, Cannabis, and Cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)","volume":"115","author":"Lopez-Quintero","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib60","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.mcna.2021.08.010_bib61","doi-asserted-by":"crossref","first-page":"113870","DOI":"10.1016\/j.psychres.2021.113870","article-title":"Adverse childhood experiences and stimulant use disorders among adults in the United States","volume":"299","author":"Tang","year":"2021","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08897077.2018.1449170","article-title":"The care of patients using methamphetamine in the emergency department: perception of nurses, residents, and faculty","volume":"40","author":"Richards","year":"2019","journal-title":"Subst Abus"},{"issue":"10","key":"10.1016\/j.mcna.2021.08.010_bib63","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1360-0443.2010.03066.x","article-title":"Withdrawal symptoms in abstinent methamphetamine- dependent subjects","volume":"105","author":"Zorick","year":"2010","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib64","first-page":"CD005031","article-title":"Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification","author":"Amato","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mcna.2021.08.010_bib65","first-page":"CD003021","article-title":"Treatment for amphetamine withdrawal","volume":"2009","author":"Shoptaw","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.mcna.2021.08.010_bib66","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamapsychiatry.2018.2383","article-title":"Targeting withdrawal symptoms in men addicted to methamphetamine with transcranial magnetic stimulation: a randomized clinical trial","volume":"75","author":"Liang","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.mcna.2021.08.010_bib67","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/add.15242","article-title":"Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?","volume":"116","author":"Brandt","year":"2021","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.mcna.2021.08.010_bib68","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00004714-200110000-00010","article-title":"Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial","volume":"21","author":"Grabowski","year":"2001","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.mcna.2021.08.010_bib69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fpsyt.2012.00077","article-title":"Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation","volume":"3","author":"Schmitz","year":"2012","journal-title":"Front Psychiatry"},{"issue":"10034","key":"10.1016\/j.mcna.2021.08.010_bib70","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(16)00205-1","article-title":"Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial","volume":"387","author":"Nuijten","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mcna.2021.08.010_bib71","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","article-title":"Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit\/hyperactivity disorder and cocaine use disorder: a randomized clinical trial","volume":"72","author":"Levin","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.drugalcdep.2004.03.008","article-title":"A\u00a0pilot trial of topiramate for the treatment of cocaine dependence","volume":"75","author":"Kampman","year":"2004","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"10.1016\/j.mcna.2021.08.010_bib73","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jamapsychiatry.2013.2295","article-title":"Topiramate for the treatment of cocaine addiction: a randomized clinical trial","volume":"70","author":"Johnson","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib74","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2013.05.026","article-title":"A\u00a0double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence","volume":"133","author":"Kampman","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib75","doi-asserted-by":"crossref","first-page":"107700","DOI":"10.1016\/j.drugalcdep.2019.107700","article-title":"Extended release mixed amphetamine salts and topiramate for cocaine dependence: a randomized clinical replication trial with frequent users","volume":"206","author":"Levin","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.mcna.2021.08.010_bib76","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.biopsych.2012.05.032","article-title":"Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial","volume":"72","author":"Mariani","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib77","first-page":"Cd007024","article-title":"Disulfiram for the treatment of cocaine dependence","author":"Pani","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2021.08.010_bib78","doi-asserted-by":"crossref","first-page":"108193","DOI":"10.1016\/j.drugalcdep.2020.108193","article-title":"A\u00a0systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders","volume":"216","author":"Chan","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.mcna.2021.08.010_bib79","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: a randomized controlled trial","volume":"68","author":"Colfax","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial","volume":"77","author":"Coffin","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.mcna.2021.08.010_bib81","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder","volume":"384","author":"Trivedi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.08.010_bib82","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mp.2011.86","article-title":"Decreased dopamine activity predicts relapse in methamphetamine abusers","volume":"17","author":"Wang","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.mcna.2021.08.010_bib83","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/appi.ajp.2010.10050748","article-title":"Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment","volume":"138","author":"Martinez","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mcna.2021.08.010_bib84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/add.12354","article-title":"Altered cingulate and insular cortex activation during risk-taking in methamphetamine dependence: losses lose impact","volume":"109","author":"Gowin JLS","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2021.08.010_bib85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fpsyt.2020.00022","article-title":"Decision-making by patients with methamphetamine use disorder receiving contingency management treatment: magnitude and frequency effects","volume":"11","author":"Lake","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.mcna.2021.08.010_bib86","series-title":"The Behaviour of organisms: an experimental analysis","author":"Skinner","year":"1938"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0306-4603(77)90003-X","article-title":"Medication take-home as a reinforcer in a methadone maintenance program","volume":"2","author":"Stitzer","year":"1977","journal-title":"Addict Behav"},{"issue":"5","key":"10.1016\/j.mcna.2021.08.010_bib88","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/ajp.150.5.763","article-title":"Achieving cocaine abstinence with a behavioral approach","volume":"150","author":"Higgins","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2021.08.010_bib89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1151\/spp032155","article-title":"Fishbowls and candy bars: using low-cost incentives to increase treatment retention","volume":"2","author":"Petry","year":"2003","journal-title":"Sci Pract Perspect"},{"issue":"9","key":"10.1016\/j.mcna.2021.08.010_bib90","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/add.12589","article-title":"Prize-based contingency management for the treatment of substance abusers: a meta-analysis","volume":"109","author":"Benishek","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/j.mcna.2021.08.010_bib91","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A\u00a0meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2021.08.010_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0376-8716(99)00068-X","article-title":"Contingency management in outpatient methadone treatment: a meta-analysis","volume":"58","author":"Griffith","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib93","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1360-0443.2006.01581.x","article-title":"Contingency management for treatment of substance use disorders: a meta-analysis","volume":"101","author":"Prendergast","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2021.08.010_bib94","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1186\/1471-2458-10-774","article-title":"Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial","volume":"10","author":"Menza","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1016\/j.mcna.2021.08.010_bib95","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.drugalcdep.2017.12.020","article-title":"The national implementation of Contingency Management (CM) in the Department of Veterans Affairs: attendance at CM sessions and substance use outcomes","volume":"185","author":"DePhilippis","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2021.08.010_bib96","series-title":"Counselor\u2019s Treatment Manual: Matrix Intensive Outpatient Treatment for People With Stimulant Use Disorders. HHS Publication No. (SMA) 13-4152","author":"Center for Substance Abuse Treatment","year":"2006"},{"key":"10.1016\/j.mcna.2021.08.010_bib97","series-title":"A\u00a0cognitive behavioral approach: treating cocaine addiction","author":"Carroll","year":"1998"},{"issue":"12","key":"10.1016\/j.mcna.2021.08.010_bib98","doi-asserted-by":"crossref","first-page":"e1002715","DOI":"10.1371\/journal.pmed.1002715","article-title":"Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis","volume":"15","author":"De Crescenzo","year":"2018","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.mcna.2021.08.010_bib99","first-page":"Cd011315","article-title":"Cognitive-behavioural treatment for amphetamine- type stimulants (ATS)-use disorders","volume":"12","author":"Harada","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2021.08.010_bib100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.drugalcdep.2008.09.015","article-title":"Enduring effects of a computer-assisted training program for cognitive behavioral therapy: a 6-month follow-up of CBT4CBT","volume":"100","author":"Carroll","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2021.08.010_bib101","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1360-0443.2007.01773.x","article-title":"\u2018Tweaking 12-Step\u2019: the potential role of 12-Step self-help group involvement in methamphetamine recovery","volume":"102","author":"Donovan","year":"2007","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.mcna.2021.08.010_bib102","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1037\/a0019195","article-title":"Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets","volume":"18","author":"Schmitz","year":"2010","journal-title":"Exp Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.mcna.2021.08.010_bib103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/20009666.2020.1742495","article-title":"Substance use disorders: diagnosis and management for hospitalists","volume":"10","author":"Pasha","year":"2020","journal-title":"J\u00a0Community Hosp Intern Med Perspect"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521001188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521001188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:14:20Z","timestamp":1777425260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712521001188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0025712521001188"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2021.08.010","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Stimulant Use and Use Disorders in a New Era","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2021.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}